Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

December 14, 2020

Study Completion Date

April 6, 2022

Conditions
Abnormal Lip
Interventions
COMBINATION_PRODUCT

Saypha® FILLER Lidocaine (HQ)

Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.

COMBINATION_PRODUCT

Saypha® FILLER Lidocaine (C1)

Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.

Trial Locations (3)

1010

Medizinisch Aesthetisches Zentrum Wien, Vienna

YUVELL - Home of Aesthetics, Vienna

1180

PW-Privatklinik Waehring GmbH, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Croma-Pharma GmbH

INDUSTRY

NCT04917588 - Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation | Biotech Hunter | Biotech Hunter